TY - JOUR
T1 - A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer
AU - Roberts, Rosebud O.
AU - Jacobson, Debra J.
AU - Girman, Cynthia J.
AU - Rhodes, Thomas
AU - Lieber, Michael M.
AU - Jacobsen, Steven J.
N1 - Funding Information:
This project was supported by research grants from the National Institutes of Health (AR30582 and DK58859) and Merck Research Laboratories.
PY - 2002
Y1 - 2002
N2 - Objective: To investigate the association between daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer. Patients and Methods: Subjects were 50- to 79-year-old white men randomly selected in January 1990 from the Olmsted County, Minnesota, community (n=1362) from among participants in a longitudinal study of lower urinary tract symptoms. At the beginning of the study, all medications that were used daily, including prescription and nonprescription NSAIDs, were ascertained by trained interviewers. Men who developed a histologically proved diagnosis of prostate cancer during a median of 66 months (maximum, 6 years) of follow-up were identified from a complete review of the community medical record. Results: Twenty-three (4%) of 569 NSAID users and 68 (9%) of 793 nonusers developed prostate cancer during follow-up (P=.001). The relative odds of prostate cancer were 0.45 (95% confidence interval [CI], 0.28-0.73) in NSAID users compared with nonusers. This inverse association with NSAID use increased with increasing age at study onset. Thus, the relative odds of prostate cancer among NSAID users were 0.9 (95% CI, 0.4-2.2) in men aged 50 to 59 years, 0.4 (95% CI, 0.2-0.8) in men aged 60 to 69 years, and 0.2 (95% CI, 0.1-0.5) in men aged 70 to 79 years compared with similarly aged men who did not use NSAIDs. Conclusion: The study findings suggest that daily use of NSAIDs may be associated with a lower incidence of prostate cancer in men aged 60 years or older. The stronger effect among older men suggests that NSAIDs may prevent the progression of prostate cancer from latent to clinical disease.
AB - Objective: To investigate the association between daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer. Patients and Methods: Subjects were 50- to 79-year-old white men randomly selected in January 1990 from the Olmsted County, Minnesota, community (n=1362) from among participants in a longitudinal study of lower urinary tract symptoms. At the beginning of the study, all medications that were used daily, including prescription and nonprescription NSAIDs, were ascertained by trained interviewers. Men who developed a histologically proved diagnosis of prostate cancer during a median of 66 months (maximum, 6 years) of follow-up were identified from a complete review of the community medical record. Results: Twenty-three (4%) of 569 NSAID users and 68 (9%) of 793 nonusers developed prostate cancer during follow-up (P=.001). The relative odds of prostate cancer were 0.45 (95% confidence interval [CI], 0.28-0.73) in NSAID users compared with nonusers. This inverse association with NSAID use increased with increasing age at study onset. Thus, the relative odds of prostate cancer among NSAID users were 0.9 (95% CI, 0.4-2.2) in men aged 50 to 59 years, 0.4 (95% CI, 0.2-0.8) in men aged 60 to 69 years, and 0.2 (95% CI, 0.1-0.5) in men aged 70 to 79 years compared with similarly aged men who did not use NSAIDs. Conclusion: The study findings suggest that daily use of NSAIDs may be associated with a lower incidence of prostate cancer in men aged 60 years or older. The stronger effect among older men suggests that NSAIDs may prevent the progression of prostate cancer from latent to clinical disease.
KW - BPH = benign prostatic hyperplasia
KW - CI = confidence interval
KW - COX-2 = cyclooxygenase 2
KW - DRE = digital rectal examination
KW - NSAID = nonsteroidal anti-inflammatory drug
KW - OR = odds ratio
KW - PSA = prostate-specific antigen
UR - http://www.scopus.com/inward/record.url?scp=0036183346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036183346&partnerID=8YFLogxK
U2 - 10.4065/77.3.219
DO - 10.4065/77.3.219
M3 - Article
C2 - 11888024
AN - SCOPUS:0036183346
SN - 0025-6196
VL - 77
SP - 219
EP - 225
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 3
M1 - 62352
ER -